Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
303 articles
A new review reveals how cellular crosstalk, non-coding RNAs, and lung microbiota drive pulmonary fibrosis — and where treatments may break through.
Scientists mapped key attack sites on measles virus proteins, finding human antibodies that powerfully neutralize MeV before and after exposure.
A novel biologic targeting IL-33 shows promising advances in COPD treatment, potentially reshaping how chronic lung disease is managed.
A new NEJM case report documents a human infection with highly pathogenic avian influenza A(H5N5), a subtype rarely reported in humans, raising pandemic preparedness concerns.
With no approved vaccine for hantavirus, experts warn the world is dangerously unprepared for future outbreaks of this deadly rodent-borne disease.
A murine arthritis study finds rapamycin suppresses neuropeptide Y, linking cellular senescence to joint inflammation via SASP cytokines.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
New research reveals E. coli dominates and suppresses S. aureus in dual-species implant biofilms, with major implications for treating polymicrobial joint infections.
JAMA publishes a timely review of IgA nephropathy, the leading cause of primary glomerulonephritis worldwide, amid a wave of new therapies.
Nephrologists from Canada and Ireland address clinical questions on IgA nephropathy, one of the most common causes of kidney failure worldwide.
